Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Finished Goods (2022 - 2026)

Ekso Bionics Holdings has reported Finished Goods over the past 4 years, most recently at $1.1 million for Q4 2025.

  • On a quarterly basis, Finished Goods rose 33.69% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 33.69% increase, with the full-year FY2025 number at $1.1 million, up 33.69% from a year prior.
  • Finished Goods reached $1.1 million in Q4 2025 per EKSO's latest filing, up from $943000.0 in the prior quarter.
  • The five-year high for Finished Goods was $1.1 million in Q4 2025, with the low at $462000.0 in Q4 2023.
  • The 4-year median for Finished Goods is $847000.0 (2023), against an average of $844166.7.
  • Peak YoY movement for Finished Goods: tumbled 46.47% in 2023, then skyrocketed 82.47% in 2024.
  • Tracing EKSO's Finished Goods over 4 years: stood at $863000.0 in 2022, then tumbled by 46.47% to $462000.0 in 2023, then skyrocketed by 82.47% to $843000.0 in 2024, then skyrocketed by 33.69% to $1.1 million in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $1.1 million, $943000.0, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.